All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Accelerated Approval to Ponatinib Plus Chemo for Newly Diagnosed Ph+ ALL

March 19th 2024

The FDA has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for the treatment of adult patients with newly diagnosed, Philadelphia chromosome–positive acute lymphoblastic leukemia.

FDA Grants Fast Track Designation to MVR-T3011 for Pretreated Recurrent/Metastatic HNSCC

March 19th 2024

The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.

Liquid Nitrogen–Based Cryoablation Leads to High RFS Rate in Low-Risk, Early-Stage Breast Cancer

March 19th 2024

Liquid nitrogen–based cryoablation elicited a 5-year local RFS rate of 96.39% in patients with low-risk, early-stage breast cancer.

Lenvatinib Plus Pembrolizumab Displays Survival Benefit in Subgroups of Patients With Endometrial Cancer

March 19th 2024

Lenvatinib plus pembrolizumab did not best chemotherapy in pMMR endometrial cancer, but did offer a survival benefit in some subgroups of patients.

Experts Share Top Highlights from the 2024 SGO Annual Meeting on Women’s Cancer

March 19th 2024

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care

March 18th 2024

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology

March 18th 2024

Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.

AI Models May Serve As Additional Genetic Counseling Resource in Gynecologic Oncology

March 18th 2024

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice

March 18th 2024

The Third Transatlantic Exchange in Oncology Conference will focus on liquid biopsy as an emerging approach in precision cancer medicine.

FDA Accepts BLA Resubmission for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma

March 18th 2024

The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.

Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy

March 18th 2024

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.

Raising Hope

March 18th 2024

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

Novel CAR T-Cell Therapy Displays Activity in Glioblastoma

March 18th 2024

Treatment with a next-generation CAR T-cell agent displayed early efficacy in a small group of patients with glioblastoma.

Disparities in Care Outcomes Persist Between Black and White Patients With Endometrioid Endometrial Carcinoma

March 18th 2024

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Nab-Sirolimus Elicits Responses in Gynecologic/Peritoneal PEComa

March 17th 2024

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer

March 17th 2024

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer

March 16th 2024

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Mirvetuximab Soravtansine Associated With Improved HRQOL in FRα+ Ovarian Cancer

March 16th 2024

Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.

SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

March 16th 2024

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.